Advertisement
Screener

LIMINATUS PHARMA, INC. (LIMN) Scorecard

2.8 / 5 stars · 68/120 Roast Me

LIMINATUS PHARMA, INC. (LIMN) Scorecard

  • 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
  • 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
  • 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
  • 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
40 QUARTERS × 3 ROAST BATTLES
2/120 All 120 Win/Lose results shown below

Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.

Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026

Complete point ledger

Each cell identifies the missing side explicitly.

QuarterTotal returnRevenue growthEPS growth
2026-Q21/3 LoseLIMN / S&P
-36.05% / 15.20% 		LoseLIMN / S&P
LIMN unavailable / 15.00% 		WinLIMN / S&P
683.33% / 50.40%
2026-Q11/3 LoseLIMN / S&P
-71.80% / -4.33% 		LoseLIMN / S&P
LIMN unavailable / 11.30% 		WinLIMN / S&P
300.00% / 27.70%
2025-Q40/3 LoseLIMN / S&P
-63.47% / 2.65% 		LoseLIMN / S&P
LIMN unavailable / 9.00% 		LoseLIMN / S&P
-83.20% / 13.40%
2025-Q30/3 LoseLIMN / S&P
-85.02% / 8.12% 		LoseLIMN / S&P
LIMN unavailable / 4.61% 		LoseLIMN / S&P
LIMN unavailable / 13.45%
2025-Q20/3 LoseLIMN / S&P
LIMN unavailable / 10.94% 		LoseLIMN / S&P
LIMN unavailable / 4.83% 		LoseLIMN / S&P
LIMN unavailable / 10.63%
2025-Q10/3 LoseLIMN / S&P
LIMN unavailable / -4.27% 		LoseLIMN / S&P
LIMN unavailable / 4.98% 		LoseLIMN / S&P
LIMN unavailable / 10.57%
2024-Q40/3 LoseLIMN / S&P
LIMN unavailable / 2.41% 		LoseLIMN / S&P
LIMN unavailable / 5.25% 		LoseLIMN / S&P
LIMN unavailable / 6.15%
2024-Q30/3 LoseLIMN / S&P
LIMN unavailable / 5.89% 		LoseLIMN / S&P
LIMN unavailable / 5.89% 		LoseLIMN / S&P
LIMN unavailable / 6.11%
2024-Q20/3 LoseLIMN / S&P
LIMN unavailable / 4.28% 		LoseLIMN / S&P
LIMN unavailable / 5.38% 		LoseLIMN / S&P
LIMN unavailable / 5.12%
2024-Q10/3 LoseLIMN / S&P
LIMN unavailable / 10.56% 		LoseLIMN / S&P
LIMN unavailable / 5.71% 		LoseLIMN / S&P
LIMN unavailable / 5.59%
2023-Q40/3 LoseLIMN / S&P
LIMN unavailable / 11.69% 		LoseLIMN / S&P
LIMN unavailable / 6.81% 		LoseLIMN / S&P
LIMN unavailable / 7.78%
2023-Q30/3 LoseLIMN / S&P
LIMN unavailable / -3.27% 		LoseLIMN / S&P
LIMN unavailable / 7.52% 		LoseLIMN / S&P
LIMN unavailable / -5.03%
2023-Q20/3 LoseLIMN / S&P
LIMN unavailable / 8.74% 		LoseLIMN / S&P
LIMN unavailable / 9.50% 		LoseLIMN / S&P
LIMN unavailable / -8.57%
2023-Q10/3 LoseLIMN / S&P
LIMN unavailable / 7.50% 		LoseLIMN / S&P
LIMN unavailable / 10.77% 		LoseLIMN / S&P
LIMN unavailable / -15.69%
2022-Q40/3 LoseLIMN / S&P
LIMN unavailable / 7.56% 		LoseLIMN / S&P
LIMN unavailable / 11.88% 		LoseLIMN / S&P
LIMN unavailable / -17.99%
2022-Q30/3 LoseLIMN / S&P
LIMN unavailable / -4.88% 		LoseLIMN / S&P
LIMN unavailable / 13.47% 		LoseLIMN / S&P
LIMN unavailable / -1.41%
2022-Q20/3 LoseLIMN / S&P
LIMN unavailable / -16.10% 		LoseLIMN / S&P
LIMN unavailable / 13.71% 		LoseLIMN / S&P
LIMN unavailable / 11.04%
2022-Q10/3 LoseLIMN / S&P
LIMN unavailable / -4.60% 		LoseLIMN / S&P
LIMN unavailable / 15.97% 		LoseLIMN / S&P
LIMN unavailable / 42.23%
2021-Q40/3 LoseLIMN / S&P
LIMN unavailable / 11.03% 		LoseLIMN / S&P
LIMN unavailable / 15.00% 		LoseLIMN / S&P
LIMN unavailable / 96.40%
2021-Q30/3 LoseLIMN / S&P
LIMN unavailable / 0.58% 		LoseLIMN / S&P
LIMN unavailable / 10.77% 		LoseLIMN / S&P
LIMN unavailable / 69.42%
2021-Q20/3 LoseLIMN / S&P
LIMN unavailable / 8.55% 		LoseLIMN / S&P
LIMN unavailable / 6.58% 		LoseLIMN / S&P
LIMN unavailable / 51.81%
2021-Q10/3 LoseLIMN / S&P
LIMN unavailable / 6.17% 		LoseLIMN / S&P
LIMN unavailable / -1.06% 		LoseLIMN / S&P
LIMN unavailable / 7.39%
2020-Q40/3 LoseLIMN / S&P
LIMN unavailable / 12.15% 		LoseLIMN / S&P
LIMN unavailable / -3.72% 		LoseLIMN / S&P
LIMN unavailable / -33.42%
2020-Q30/3 LoseLIMN / S&P
LIMN unavailable / 8.93% 		LoseLIMN / S&P
LIMN unavailable / -2.04% 		LoseLIMN / S&P
LIMN unavailable / -27.10%
2020-Q20/3 LoseLIMN / S&P
LIMN unavailable / 20.54% 		LoseLIMN / S&P
LIMN unavailable / -0.46% 		LoseLIMN / S&P
LIMN unavailable / -27.11%
2020-Q10/3 LoseLIMN / S&P
LIMN unavailable / -19.60% 		LoseLIMN / S&P
LIMN unavailable / 3.47% 		LoseLIMN / S&P
LIMN unavailable / -14.75%
2019-Q40/3 LoseLIMN / S&P
LIMN unavailable / 9.07% 		LoseLIMN / S&P
LIMN unavailable / 5.36% 		LoseLIMN / S&P
LIMN unavailable / 2.99%
2019-Q30/3 LoseLIMN / S&P
LIMN unavailable / 1.70% 		LoseLIMN / S&P
LIMN unavailable / 5.02% 		LoseLIMN / S&P
LIMN unavailable / 0.21%
2019-Q20/3 LoseLIMN / S&P
LIMN unavailable / 4.30% 		LoseLIMN / S&P
LIMN unavailable / 6.64% 		LoseLIMN / S&P
LIMN unavailable / 8.65%
2019-Q10/3 LoseLIMN / S&P
LIMN unavailable / 13.65% 		LoseLIMN / S&P
LIMN unavailable / 8.12% 		LoseLIMN / S&P
LIMN unavailable / 14.29%
2018-Q40/3 LoseLIMN / S&P
LIMN unavailable / -13.52% 		LoseLIMN / S&P
LIMN unavailable / 9.05% 		LoseLIMN / S&P
LIMN unavailable / 18.23%
2018-Q30/3 LoseLIMN / S&P
LIMN unavailable / 7.71% 		LoseLIMN / S&P
LIMN unavailable / 10.21% 		LoseLIMN / S&P
LIMN unavailable / 19.06%
2018-Q20/3 LoseLIMN / S&P
LIMN unavailable / 3.43% 		LoseLIMN / S&P
LIMN unavailable / 9.03% 		LoseLIMN / S&P
LIMN unavailable / 14.46%
2018-Q10/3 LoseLIMN / S&P
LIMN unavailable / -0.76% 		LoseLIMN / S&P
LIMN unavailable / 7.68% 		LoseLIMN / S&P
LIMN unavailable / 12.46%
2017-Q40/3 LoseLIMN / S&P
LIMN unavailable / 6.64% 		LoseLIMN / S&P
LIMN unavailable / 7.03% 		LoseLIMN / S&P
LIMN unavailable / 13.82%
2017-Q30/3 LoseLIMN / S&P
LIMN unavailable / 4.48% 		LoseLIMN / S&P
LIMN unavailable / 5.68% 		LoseLIMN / S&P
LIMN unavailable / 17.57%
2017-Q20/3 LoseLIMN / S&P
LIMN unavailable / 3.09% 		LoseLIMN / S&P
LIMN unavailable / 4.83% 		LoseLIMN / S&P
LIMN unavailable / 17.74%
2017-Q10/3 LoseLIMN / S&P
LIMN unavailable / 6.07% 		LoseLIMN / S&P
LIMN unavailable / 3.67% 		LoseLIMN / S&P
LIMN unavailable / 13.32%
2016-Q40/3 LoseLIMN / S&P
LIMN unavailable / 3.82% 		LoseLIMN / S&P
LIMN unavailable / 2.09% 		LoseLIMN / S&P
LIMN unavailable / 7.05%
2016-Q30/3 LoseLIMN / S&P
LIMN unavailable / 3.85% 		LoseLIMN / S&P
LIMN unavailable / 0.20% 		LoseLIMN / S&P
LIMN unavailable / -3.15%

Dividend-reinvested, split-adjusted total return

1Y · 2025-08-29 to 2026-08-27

MetricLIMN total returnS&P 500 Total Return Index
Total return-96.75%20.78%
Annualized return-96.75%20.78%

5Y · 2025-05-02 to 2026-08-27

MetricLIMN total returnS&P 500 Total Return Index
Total return-98.91%83.14%
Annualized return-59.46%12.86%

10Y · 2025-05-02 to 2026-08-27

MetricLIMN total returnS&P 500 Total Return Index
Total return-98.91%319.30%
Annualized return-36.33%15.41%

Calculation rules

window
Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
return Basis
Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
point Rule
Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
frequency
Quarter endpoints only.
fundamentals
Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
non Scoring

Snapshot captured 2026-09-04.

Similar stocks

Stock NameCountryMarket CapPE Ratio
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Advertisement